KSHV LANA1 sequence that inhibits protein turnover and CTL antigen processing
- 詳細技術說明
- None
- *Abstract
-
Vaccines can be made against KSHV by generating a protein with the central repeat domain deleted. These antigens will have enhanced immunogenicity against the remaining N-terminal and C-terminal peptides. Alternatively, the central repeat domain can be cloned as a fusion protein into a gene delivery vector. Expression of the central repeat domain will increase protein stabilization and decrease immunogenicity of the transgenic protein. The LANA1 repeat domain may be a useful and simple means to increase gene therapy delivered protein expression.Possible applications of this invention include:-KSHV vaccine-Gene therapyProvisional Patent Application Filed
- *Principal Investigation
-
Name: Yuan Chang, Professor, Pathology
Department: Med-Pathology
Name: Patrick Moore, Director
Department: Med-Microbiology and Molecular Genetics
- 國家/地區
- 美國
欲了解更多信息，請點擊 這裡
